

- **02.28.23 - Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development (PR)**
 - Mr. Shalish joins Frontier from the global business unit of Novo Nordisk. Prior to his tenure with Novo Nordisk, Mr. Shalish led the business development and alliance management functions at Dicerna Pharmaceuticals. While at Dicerna, he facilitated collaborations with Roche and Novo Nordisk, leading up to the successful acquisition of Dicerna by Novo Nordisk. Mr. Shalish was also responsible for overseeing partnerships with Boehringer Ingelheim, Eli Lilly, Alexion, and Alnylam. Mr. Shalish brings deep knowledge of the biotech ecosystem from his work at successful companies including Moderna, Warp Drive Bio, Cubist Pharmaceuticals and ActivBiotics. He began his career as a research scientist at Massachusetts General Hospital. Mr. Shalish received his MBA from Boston University and his Bachelor of Science in Biology from Gettysburg College in Pennsylvania. Frontier is advancing a deep pipeline of wholly-owned precision medicines against the most important drivers of cancer. The company's lead candidate, FMC-376, is a direct dual inhibitor of active and inactive KRASG12C. By completely blocking both forms of the KRAS mutation, FMC-376 has the potential to overcome the non-response and resistance seen with existing single-acting KRASG12C inhibitors.
- **02.28.23 - Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer (PR)**
 - Lyra Therapeutics, Inc. (Nasdaq: LYRA)(the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the appointment of John Bishop, Ph.D., as Chief Technology Officer, effective February 27, 2023. Dr. Bishop will lead the commercial scale-up of Lyra's manufacturing operations for the Company's late-stage product candidates, LYR-210 and LYR-220. He joins Lyra from Forma Therapeutics (acquired by Novo Nordisk), where he was Chief Technology Officer. Prior to Forma, he served as senior vice president of pharmaceutical sciences at Epizyme, where he held overall responsibility for the CMC and quality assurance functions. Previously, he held leadership positions in process development and manufacturing at Genocsa Biosciences, Momenta Pharmaceuticals, Millennium Pharmaceuticals (now Takeda), DuPont-Merck Pharmaceutical and Alcon Laboratories. Dr. Bishop earned Bachelor of Science degrees in chemistry and German from Tufts University, a Ph.D. in organic chemistry from University of California, Berkeley, and an MBA from Northeastern University. He served as a Captain in the Chemical Corps for the U.S. Army on active duty from 1990 to 1991.
- **02.28.23 - Nationwide Children's spinoff Andelyn Biosciences promotes CEO from within (bizjournal)**
 - Wade Macedone was promoted to CEO after serving as COO since the biotech started building its Columbus facility in October 2020. Before that he led the gene therapy manufacturing operations that the hospital spun out to form the for-profit affiliate.
- **02.28.23 - Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development (PR)**
 - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development. Most recently, Dr. Crystal served as Chief Medical Officer of C4 Therapeutics where he oversaw the advancement of several oncology drug candidates into clinical trials. Prior to that, Dr. Crystal was at Novartis Oncology where he led multiple early clinical development programs. Dr. Crystal has served as a medical oncologist at Massachusetts General Hospital where he studied resistance mechanisms to targeted therapies. He completed his internal medicine training at Massachusetts General Hospital and his fellowship in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana-Farber Cancer Institute. Dr. Crystal holds an M.D., as well as a Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine.
- **02.27.23 - Ellodi Pharmaceuticals Welcomes Debra Silberg MD, PhD, FAGC to its Board of Directors**
 - Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company dedicated to the continued development of APT-1011, a novel, investigational oral therapy for the treatment of Eosinophilic Esophagitis (EoE), announced today that Debra Silberg, MD, PhD, FAGC has joined the company's board of directors. Dr. Silberg will also serve as a Scientific Advisor. Dr. Silberg is an accomplished life sciences executive with deep experience across all stages of drug development. She serves as a Scientific Advisor to multiple pharmaceutical companies and has held clinical leadership roles at AstraZeneca, Shire, and most recently, Takeda, where she served as the company's Global Vice President of Clinical Development and Clinical Science Head for Gastroenterology. In this role, she was responsible for the Gastrointestinal (GI) program team, which included approximately 30 physicians and clinical scientists across the US, Europe, China, and Japan who were focused on several GI diseases, including EoE. Additionally, Dr. Silberg oversaw the clinical aspects and led discussions with regulatory authorities (FDA and EMA) to facilitate the advancement of numerous GI development programs.

- 02.27.23 - Billy Dunn, FDA official in charge of neuroscience drug reviews, to leave agency ([biopharmadive](#))
 - Billy Dunn, a top Food and Drug Administration official who played a key role in recent approvals of new therapies for Alzheimer's and ALS, is leaving the agency. His departure was announced in an email to FDA staff sent by Peter Stein, head of the regulator's Office of New Drugs. Teresa Buracchio, an FDA veteran and currently the acting deputy director of the Office of Neuroscience, will take Dunn's place on an acting basis. She has also been appointed to the deputy director role on a permanent basis, Stein wrote. Dunn, who joined the FDA in 2005 from the National Institute of Neurological Disorders and Stroke, rose through the regulator's ranks, becoming director of the then Division of Neurological Products in 2013. He is the first director of the Office of Neuroscience, a group he helped design and stand up, according to Stein's email.
- 02.27.23 - ONI Appoints Paul Scagnetti as CEO to Implement Next Chapter of Growth ([PR](#))
 - Paul brings over 25 years of experience in the life science and technology markets and comes with a proven track of success for both large and small companies. Prior to joining ONI, Paul's most recent role was Vice President of Corporate and Business Development at Illumina, where he led M&A, partnerships, and licensing. Paul's experience spans international leadership roles where his responsibilities ranged from general management, new business development, and strategic planning at companies such as FEI and Intel. ONI's mission is to accelerate scientific discovery and fight disease by enabling everyone to visualize, understand, and share the microscopic details of life. ONI's first product, the Nanoimager, is the world's first desktop, super-resolution, single-molecule imaging platform capable of visualizing and tracking individual molecules in complex systems such as nanoparticles, living cells, and tissue with 20 nm resolution.
- 02.23.23 - Delfi Promotes Jenn Buechel to President and Chief Operating Officer ([PR](#))
 - Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, announces the promotion of Jenn Buechel to the new role of President & Chief Operating Officer. An early leader in the liquid biopsy field, Jenn has held executive leadership roles at Guardant Health and GRAIL before joining Delfi. In addition to her industry work, Jenn is active in non-profit leadership, and is a Health Innovators Fellow with The Aspen Institute. She earned a Master's in Systems Engineering and an MBA from Stanford University, and a Bachelors in Chemical Engineering (Applied Science) from Queen's University in Canada.
- 02.23.23 - Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader ([PR](#))
 - Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin, Ph.D. has been appointed to the board of directors of the company and is transitioning from chief scientific officer into the role of distinguished scientist and strategic leader, remaining a key member of Avidity's team. W. Michael Flanagan, Ph.D., has been promoted from chief technical officer to chief scientific and technical officer.
- 02.17.23 - Gilead's Shaw to step down from role running cell therapy unit ([biopharmadive](#))
 - Top Gilead Sciences executive Christi Shaw will leave the company at the end of March after more than three years running the drugmaker's Kite cell therapy division, Gilead announced Friday. Over that time, Shaw helped grow Kite into a leading producer of the complex medicines and an important contributor to Gilead's overall business, which has long been dominated by pills for HIV and hepatitis C. Last year, sales of the Gilead's two marketed cell therapies, approved to treat certain blood cancers, totaled nearly \$1.5 billion, or about 6% of the company's revenue outside of its COVID-19 drug Veklury. She's also overseen an expansion of Kite's manufacturing capabilities, which are critical for producing personalized cellular medicines. The kind of cell therapy Kite specializes in, known as CAR-T, requires immune cells to be extracted from each individual patient, reengineered in a laboratory to more effectively target cancer and then reinfused. The multi-week process involves careful managing of supply chains spanning states, countries and oceans. Gilead said Shaw will work with CEO Daniel O'Day and the Kite team to hand off her responsibilities while the company searches for her replacement.

About Berke Search

The Berke Executive Search team is comprised of seasoned and engaged partners who lead our highly specialized firm with an unwavering commitment to excellence and integrity. With over two decades of experience conducting searches for C-Suite, Senior Commercial, Scientific Leadership, and specialized functional leadership disciplines, we have developed deep relationships and a large network of top talent. Our deep experience and expertise benefits clients by shrinking timelines and lowering talent acquisition costs. In addition, our nimble size (boutique) and highly selective client base virtually eliminate conflict of interest and off-limit issues; we execute only a select number of search pools to ensure our resources are maximized and enable superior success rates.

Visit us at [Berkesearch.com](https://www.berkesearch.com)